Get the Stockscreener App
1.40
0.00%
0.00
After Hours:
1.34
-0.06
-4.29%
Werewolf Therapeutics Inc stock is traded at $1.40, with a volume of 198.03K.
It is up +0.00% in the last 24 hours and up +17.65% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$1.40
Open:
$1.4
24h Volume:
198.03K
Relative Volume:
0.39
Market Cap:
$62.82M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-1.3462
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
+6.87%
1M Performance:
+17.65%
6M Performance:
+2.94%
1Y Performance:
-48.91%
1-Day Range:
$1.33
$1.4278
1-Week Range:
$1.25
$1.50
52-Week Range:
$0.595
$4.18
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.40 | 58.78M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
What analysts say about Werewolf Therapeutics Inc. stockHigh-velocity gains - jammulinksnews.com
How Werewolf Therapeutics Inc. stock performs during market volatilityFree Stock Trading Community - Newser
What drives Werewolf Therapeutics Inc. stock priceFree Capital Growth Strategies - jammulinksnews.com
Why Werewolf Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Shares - Newser
Is Werewolf Therapeutics Inc. a good long term investmentConsistently exceptional gains - Autocar Professional
Werewolf Therapeutics Inc. Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com
What makes Werewolf Therapeutics Inc. stock price move sharplyInvestor Favorite Picks - Newser
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know - MSN
Vontobel Holding Ltd. Acquires New Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics to Present Innovative IL-2 INDUKINE Development at KidneyCAN 7th Annual Kidney Cancer Research Summit - Nasdaq
Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit - GlobeNewswire
Werewolf Therapeutics: A High-Risk, High-Potential Bet in Cancer Immunotherapy - criticalcontrolroomworld.com
Werewolf Therapeutics (NASDAQ:HOWL) Trading Up 1% – What’s Next? - Defense World
Werewolf Therapeutics Adopts New Bylaws and Elects Directors - TipRanks
Two Sigma Investments LP Sells 87,168 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics to Participate in the BIO International Convention - GlobeNewswire
Jane Street Group LLC Acquires 39,564 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Two Sigma Advisers LP Sells 117,200 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Sold by Millennium Management LLC - Defense World
Deutsche Bank AG Buys 83,172 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Northern Trust Corp Acquires 16,640 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Bank of America Corp DE Lowers Stock Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics Announces Q1 2025 Financial Results - MSN
Werewolf Therapeutics Leaders to Reveal Latest Cancer Treatment Progress at Major Healthcare Conference - Stock Titan
Werewolf Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference - GlobeNewswire
D. E. Shaw & Co. Inc. Makes New Investment in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy Rating Maintained | HOWL Stock News - GuruFocus
Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy R - GuruFocus
Werewolf Therapeutics (HOWL) Stock Price, News & Analysis - MarketBeat
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):